In this setting, they have recommended to avoid SGLT2 inhibitors in all patients with risk factors for developing symptoms or serious complications of COVID-19, such as patients with a history of hypertension, T2DM, atherosclerotic cardiovascular disease, heart failure and/or estimated GFR <25 mL/min/1.73 m2. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.